We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Bladder Cancer

Journal Scan / Research · August 11, 2021

Predictive Model for Systemic Recurrence Following Cisplatin-Based Neoadjuvant Chemotherapy and Radical Nephroureterectomy for High-Risk Upper-Tract Urothelial Carcinoma

Urologic Oncology: Seminars and Original Investigations

 

Additional Info

Urologic Oncology: Seminars and Original Investigations
Predictive Model for Systemic Recurrence Following Cisplatin-Based Neoadjuvant Chemotherapy and Radical Nephroureterectomy for High Risk Upper Tract Urothelial Carcinoma
Urol. Oncol 2021 Jul 28;[EPub Ahead of Print], RA Ghandour, Y Freifeld, J Cheaib, N Singla, X Meng, A Kenigsberg, A Bagrodia, S Woldu, J Hoffman-Censits, D Enikeev, L Rapoport, FG Petros, JD Raman, PM Pierorazio, SF Matin, V Margulis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading